Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Matrix Biol. 2016 Nov 11;62:28–39. doi: 10.1016/j.matbio.2016.11.001

Figure 5. HA35 treatment prevents increased gut permeability during DSS exposure.

Figure 5

A. Groups of mice (5 mice per group) were orally treated with HA35 (300µg/mouse) or water once per day for 5 days. On the day of euthanasia, mice were gavaged with FITC labeled-4kDa dextran 4 hours before serum collection. FITCdextran in serum was measured by spectroflurorometer. The serum of mice not given FITC-dextran (n=2) was used as the negative control, and the O.D. value was subtracted from all samples. Each dot represents an individual mouse in the graph. B. Groups of mice (5 mice per group) were orally treated with HA35 (300µg/mouse) or water once daily for 5 days before as well as 3 days during 2.5% DSS administration. On the day of euthanasia, mice were gavaged with FITC labeled-4 kDa dextran 4 hours before serum collection. The one-tailed Mann-Whitney test was used to test the significance of difference between groups, and a significant difference is indicated in the figure (*, p<0.05). N.S.=not significant. Error bars=S.E.M.